Ganetespib (STA-9090)

Catalog No.S1159

Ganetespib (STA-9090) Chemical Structure

Molecular Weight(MW): 364.4

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Size Price Stock Quantity  
In DMSO USD 302 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Loss of viability (Z score) resulting from HSP90 inhibition (HSP90i; ganetespib, 5 nM) in FANCA null GM6914 cells transduced with retroviruses encoding FANCA wild-type (squares; WT) or empty vector control (circles; null) in the presence (black symbols) of MMC (31.6 nM) or DMSO control (gray symbols). Data from three independent experiments are presented as mean ± SEM.

    Cell, 2017, 168(5):856-866. Ganetespib (STA-9090) purchased from Selleck.

    Breast cancer (MDA-MB-231), pancreatic cancer (PaTu2), lung cancer (A549), colon cancer HCT-116, and acute myeloid leukemia (SKM1) cell lines were incubated with increasing amounts of PU-H71 and STA-9090 as indicated. Western blot analysis with PRKD2, cleaved PARP, and cleaved caspase-9 antibodies is depicted.

    Cancer Res 2014 10.1158/0008-5472.CAN-14-1017. Ganetespib (STA-9090) purchased from Selleck.

  • Western blot analysis of the expression of Brd4 and Hsp90 from whole-cell lysates of Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 at indicated concentrations for 24 h (B), and in Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 (200 nM) at indicated time points (C).

    Hum Mol Genet, 2015, 10.1093/hmg/ddv136. Ganetespib (STA-9090) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Targets
HSP90 [1]
(OSA 8 cells)
4 nM
In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL60 MYTBdI9xfG:|aYOgRZN{[Xl? NHnhfWw{OC96MD:xOVAwOjVyIH7N NYPzWGZrOjRxNEivO|IhcA>? MojHbY5lfWOnczDkc5NmKGSncHXu[IFvfCCrbnT1Z5Rqd25ib3[gZZBweHSxc3nz NVXFSnhyOjV6OEK1OVA>
MV411 MXfBdI9xfG:|aYOgRZN{[Xl? NGfXUZY{OC96MD:xOVAwOjVyIH7N Ml;yNlQwPDhxN{KgbC=> NUKycWRrcW6mdXPld{Bld3OnIHTldIVv\GGwdDDpcoR2[3Srb36gc4Yh[XCxcITvd4l{ NEnFNVYzPTh6MkW1NC=>
MGC-803 NYfPOHRbS2WubDDWbYFjcWyrdImgRZN{[Xl? M3zoSVAvOS1zMECwJI5O MV63NkBp NFjyb5hqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M4fad|I2PTlyOEC1
SGC-7901 NX3vfpFmS2WubDDWbYFjcWyrdImgRZN{[Xl? M4XSXVAvOS1zMECwJI5O NVPQT|ZbPzJiaB?= MXjpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MlTENlU2QTB6MEW=
MKN-28 NH7tbpBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWKwMlEuOTByMDDuUS=> M3j6UVczKGh? MYrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MlLONlU2QTB6MEW=
MGC-803 MYDGeY5kfGmxbjDBd5NigQ>? MUGwMlEuOTByMDDuUS=> M1:3TVI1KGh? MUPpcoR2[2W|IFeyM20h[2WubD3jfYNt\SCjcoLld5Q> MWKyOVU6ODhyNR?=
HCT-116 M2frS2Z2dmO2aX;uJGF{e2G7 MXe1NI5O MWiyOEBp NXnXe41NTE2VTx?= MUjpcoR2[2WmIFewM2cyKGG{cnXzeC=> MnX6NlUzOTB5OUS=
HT-29 NGXMPXJHfW6ldHnvckBCe3OjeR?= MVW1NI5O NV34TVlCOjRiaB?= NYr0cmxjTE2VTx?= MlfrbY5lfWOnZDDHNE9IOSCjcoLld5Q> NWC2TFJHOjV{MUC3PVQ>
SCC25 MoDjR5l1d3irY3n0fUBCe3OjeR?= NEPNNo8yOC93MDDuUS=> NHPXUo8zPCCq NFzkfmNl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> M13FOFI2OjB3NEOw
FUDA MWrDfZRwgGmlaYT5JGF{e2G7 NYTPcoFOOTBxNUCgcm0> MV:yOEBp MmXE[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5 MXeyOVIxPTR|MB?=
Detroit562 NULadmF2S3m2b4jpZ4l1gSCDc4PhfS=> M2PhcVExNzVyIH7N NFP1e2EzPCCq MYHk[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm= NFrwZnkzPTJyNUSzNC=>
CAL27 NXTIdHpHS3m2b4jpZ4l1gSCDc4PhfS=> MWWxNE82OCCwTR?= MoLYNlQhcA>? NU\IblJ{\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 M{LaXlI2OjB3NEOw
DSH1 MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDJboJ7UUN3ME22JI5O NWrqXItQOjR5OES4N|k>
SW-1710 M3HJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrJe2RPUUN3ME22JI5O NIrxWVIzPDd6NEizPS=>
T24 NH;oSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\vS4pKSzVyPUegcm0> NGW5RXkzPDd6NEizPS=>
RT112 M3fneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnic2JKSzVyPUmgcm0> MVqyOFc5PDh|OR?=
639-V Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M321R2lEPTB;MUCgcm0> NVjlUWg{OjR5OES4N|k>
SCaBER MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfGTWM2OD1zMDDuUS=> M3ixNVI1Pzh2OEO5
BFTC NUDJcWhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDVcIw5UUN3ME2xO{BvVQ>? NEPjXIYzPDd6NEizPS=>
J82 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX6U4tYUUN3ME2xPEBvVQ>? MWSyOFc5PDh|OR?=
HT-1376 M4PwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF64fnpKSzVyPUKxJI5O NWW4RYhWOjR5OES4N|k>
647-V NXv2WodnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJ5IH7N MkjtNlQ4QDR6M{m=
UM-UC3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTN|IH7N MlH5NlQ4QDR6M{m=
LB831-BLC M1XV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjpeYlFUUN3ME2zOEBvVQ>? M1q4d|I1Pzh2OEO5
KU-19-19 NVLuPGh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN4IH7N NEi4VHEzPDd6NEizPS=>
35612 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvnc5R2UUN3ME2zPEBvVQ>? Mo[1NlQ4QDR6M{m=
5637 NUP5bnM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfse3gyUUN3ME20OEBvVQ>? NYXufZpUOjR5OES4N|k>
HT-1197 NHzTcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHIeVdKSzVyPUWzJI5O MY[yOFc5PDh|OR?=
MGH-U3 M362fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[zVm9KSzVyPUWzJI5O MWWyOFc5PDh|OR?=
TCCSUP NYWwUnNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;ETWM2OD1zNEKgcm0> M{TTdlI1Pzh2OEO5
RT4 M4X5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr5N|dKSzVyPUG3N|Mhdk1? M{jWNFI1Pzh2OEO5
SW780 NIP2[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXDTWM2OD1|NEWxJI5O M{j5UlI1Pzh2OEO5
RKO NGDiOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Xwe2lEPTB;NDDuUS=> MkfwNlQ3QDJ5NEe=
LS-411 N MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\QRmlEPTB;NTDuUS=> NYHBcZlbOjR4OEK3OFc>
SW620 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[yTWM2OD16IH7N NYjwdpk4OjR4OEK3OFc>
HCT-15 NEDm[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXRTWM2OD16IH7N M3rWdVI1Pjh{N{S3
HuTu-80 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\lXHBKSzVyPUGzJI5O NVj5SGFrOjR4OEK3OFc>
HCT 116 MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnqwTWM2OD1zNDDuUS=> Ml3uNlQ3QDJ5NEe=
COLO-205 M3nB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF2IH7N MVuyOFY5Ojd2Nx?=
NCI-H747 MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTzTWM2OD1zNzDuUS=> MYOyOFY5Ojd2Nx?=
COLO-678 NIrYeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS5TWM2OD1{MTDuUS=> NYm2PHEyOjR4OEK3OFc>
LoVo NVeyfnJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJ{IH7N NYXK[WE6OjR4OEK3OFc>
LS-1034 NXLyUHByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvPe4NqUUN3ME2zNUBvVQ>? NFu0SXIzPDZ6Mke0Oy=>
SNU-C2B MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzobYRKSzVyPUS1JI5O Mm\ZNlQ3QDJ5NEe=
LS-123 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu2cFNKSzVyPUezJI5O NV6wfGwzOjR4OEK3OFc>
SK-CO-1 M1LCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfUcFRKSzVyPUixJI5O MV6yOFY5Ojd2Nx?=
HCC2998 NYPmc2R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37QfmlEPTB;MUK4JI5O MYWyOFY5Ojd2Nx?=
MDA-MB-231 MY\GeY5kfGmxbjDBd5NigQ>? M1LPRlExOCCwTR?= M4HJTVMxKG2rbh?= MofQbY5pcWKrdIOgZYNkfW23bHH0bY9vKG:oIFjJSk0y|rF? M17FclI1OjR6Mk[1
MDA-MB-435 Mo[5SpVv[3Srb36gRZN{[Xl? MWqxNFAhdk1? Mn34N|AhdWmw NXH4c4s5cW6qaXLpeJMh[WOldX31cIF1cW:wIH;mJGhKTi1zzsG= MX:yOFI1QDJ4NR?=
BT-20  NU\aUnlTTnWwY4Tpc44hSXO|YYm= NH71XoYyODBxMkWwJI5O M2W4blI1KGh? M1TjVZJme3WudHXkJIlvKGFiZH;z[U1l\XCnbnTlcpQh\GW|dHHibYxqgmG2aX;uJI9nKEWJRmKsJGlITi2LUjygUWVVNCCjbnSgR3JCTg>? NFvsRpMzPDF5M{W0NS=>
MDA-MB-231 M1XH[mZ2dmO2aX;uJGF{e2G7 Mmi4NVAxKG6P NUe2d3Q{OjRiaB?= MX3pcohq[mm2czD0bIUhdWmpcnH0c5J6KGGwZDDpcpZie2m4ZTDjZZBi[2m2edMg NHTFToozPDF5M{W0NS=>
H82 M1e0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTNyLkK3JI5O NVfMemRDOjRzNk[1NFU>
GLC4 M3;ESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rxZWlEPTB;MkCuOFchdk1? MnPNNlQyPjZ3MEW=
H69 NF3qdo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[5[4dzUUN3ME24N{4{PiCwTR?= M3LmW|I1OTZ4NUC1
H128 NWPSVJlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTZ7LkW1JI5O NHPOXWozPDF4NkWwOS=>
H146 NF36fotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJ6LkWxJI5O NGLtc|gzPDF4NkWwOS=>
H187 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3VTWM2OD1{ND65PUBvVQ>? NEjWW5kzPDF4NkWwOS=>
H526 MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;hTWM2OD1{MT62OEBvVQ>? M1H3c|I1OTZ4NUC1
N592 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF2LkGyJI5O MXuyOFE3PjVyNR?=
H620 M3TTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTN{Lk[3JI5O NVPxbW5YOjRzNk[1NFU>
H792 NXTmc4JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTR3LkC3JI5O NH3rR5EzPDF4NkWwOS=>
H1173 MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF{Lk[yJI5O MUOyOFE3PjVyNR?=
AC3 M2HmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnWTWM2OD1{NT65JI5O Mk\CNlQyPjZ3MEW=
H82 MYLGeY5kfGmxbjDBd5NigQ>? NILFXVQ{OCCwTR?= MUK3NkBp M1yx[olv\HWlZYOgdIVze2m|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=> M1v0blI1OTZ4NUC1
GLC4 NV60dY5PTnWwY4Tpc44hSXO|YYm= M{fXd|MxKG6P MlLJO|IhcA>? M{PzOIlv\HWlZYOgdIVze2m|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=> MUeyOFE3PjVyNR?=
H146  NWrXcZBCTnWwY4Tpc44hSXO|YYm= M2fmOVMxKG6P M3XoV|czKGh? NW\k[Jh7cW6mdXPld{Bx\XK|aYP0[Y51KEd{L12gdIhie2ViYYLy[ZN1 NFHleYozPDF4NkWwOS=>
OVCAR-5 NH\zOGlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2\MZlAuOTByMDDuUS=> M1jsb|czKGh? NEjGenVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MXmyN|kxODF|Nh?=
OVCAR-8 MoP3R4VtdCCYaXHibYxqfHliQYPzZZk> Mn\FNE0yODByIH7N NYL3Zml4PzJiaB?= M2LvS4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MU[yN|kxODF|Nh?=
A1847 NWjre5c1S2WubDDWbYFjcWyrdImgRZN{[Xl? NEL4bIsxNTFyMECgcm0> NVvIWZBZPzJiaB?= NX3JfIhQcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MVOyN|kxODF|Nh?=
SKOV-3 NFv5enBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXSwMVExODBibl2= NYS4SZlHPzJiaB?= NXLvZ4lTcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NGTCT|kzOzlyMEGzOi=>
OVCAR-5 NULySJdESXCxcITvd4l{KEG|c3H5 M1;h[|ExNTFyMDDuUS=> NUXjcINHOjRxNEivO|IhcA>? MlS3bY5lfWOnczDhdI9xfG:|aYOgeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnSueR?= NYLlV44zOjN7MECxN|Y>
OVCAR-8 NV63ZpdTSXCxcITvd4l{KEG|c3H5 NEnsZ3YyOC1zMECgcm0> M1XVflI1NzR6L{eyJIg> MliybY5lfWOnczDhdI9xfG:|aYOgeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnSueR?= M4rGWFI{QTByMUO2
A1847 MnPnRZBweHSxc3nzJGF{e2G7 MljaNVAuOTByIH7N NFHYVI0zPC92OD:3NkBp MVTpcoR2[2W|IHHwc5B1d3OrczD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfGy7 M1;p[FI{QTByMUO2
H2228 M4P6NWNmdGxiVnnhZoltcXS7IFHzd4F6 MkTiNE0yODByIH7N NV24Z3FCPzJiaB?= MVHJR|UxRTF|IH7N MYSyN|U{OzJ4NR?=
H3122 MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlOzNE0yODByIH7N M3raUlczKGh? MXTJR|UxRTFyIH7N M1XSS|I{PTN|Mk[1
K008 NFPXT3VE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYTtSZhFUUN3ME22NEBvVQ>? M4PWVFI{PDF6NUKz
K028 NUHvNpF5S2WubDDWbYFjcWyrdImgRZN{[Xl? MlzNTWM2OD16NDDuUS=> NWTUW3g2OjN2MUi1NlM>
K029 Mnr3R4VtdCCYaXHibYxqfHliQYPzZZk> M{DHd2lEPTB;NE[gcm0> M1mxV|I{PDF6NUKz
M23 MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mlj0TWM2OD1|Nz61JI5O NH7aWFYzOzRzOEWyNy=>
K033 NHjmV3lE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWHJR|UxRTd3LkWgcm0> NH7wO2MzOzRzOEWyNy=>
K008 NH6zbpVHfW6ldHnvckBCe3OjeR?= NGDteYozPTBibl2= M1v1VVI1KGh? MYHpcoR2[2W|IFeyJIFzemW|dB?= M1rMOVI{PDF6NUKz
K028 MkW5SpVv[3Srb36gRZN{[Xl? MnnVNlUxKG6P MVmyOEBp MXfpcoR2[2W|IFeyJIFzemW|dB?= NFXhdYYzOzRzOEWyNy=>
K029 MkjlSpVv[3Srb36gRZN{[Xl? NYjBbJRYOjVyIH7N NHzoN3EzPCCq NY[xRpVZcW6mdXPld{BIOSCjcoLld5Q> NX\NXoZbOjN2MUi1NlM>
M23 NI\xcGJHfW6ldHnvckBCe3OjeR?= M{mxcFI2OCCwTR?= MVSyOEBp Mmj3bY5lfWOnczDHNUBidmRiR{KvUUBienKnc4S= NV3lPW9FOjN2MUi1NlM>
K033 NHPSdWZHfW6ldHnvckBCe3OjeR?= NXjtc3R1OjVyIH7N M2S1c|I1KGh? MnntbY5lfWOnczDhJI1w\GW|dDDpcoNz\WG|ZTDpckBIOSCyb4D1cIF1cW:w MYSyN|QyQDV{Mx?=
K008 M134NGFxd3C2b4Ppd{BCe3OjeR?= M4DFUVExOCCwTR?= Mk\QO|IhcA>? NV3qWpBze2mpbnnmbYNidnSueTDpcoR2[2W|IHHwc5B1d3Orcx?= NXnZNXhwOjN2MUi1NlM>
K028 MWrBdI9xfG:|aYOgRZN{[Xl? Mk\tNVAxKG6P NULBV3pvPzJiaB?= NFzlNm9{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| NWjjZZFkOjN2MUi1NlM>
K029 NYDOOGNbSXCxcITvd4l{KEG|c3H5 NEXONVYyODBibl2= M{XnU|czKGh? NVLxeo57e2mpbnnmbYNidnSueTDpcoR2[2W|IHHwc5B1d3Orcx?= MXGyN|QyQDV{Mx?=
M23 M{Dt[GFxd3C2b4Ppd{BCe3OjeR?= MkDoNVAxKG6P M4PIRlczKGh? MmjFd4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>? MWSyN|QyQDV{Mx?=
K033 MkTFRZBweHSxc3nzJGF{e2G7 NVizTGV[OTByIH7N M1;IUFczKGh? MV;zbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{ M1KyVlI{PDF6NUKz
RD MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTQTWM2OD16IH7N MmnLNlM{ODN5NEG=
Rh41 NFPOcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFyLkSgcm0> M2rtWVI{OzB|N{Sx
Rh18 NXjMWpQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTZwMjDuUS=> NVrobJBlOjN|MEO3OFE>
Rh30 NXXzN|BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Kx[GlEPTB;NT62JI5O MYeyN|MxOzd2MR?=
BT-12 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS0TWM2OD1zND6zJI5O NFT1dIozOzNyM{e0NS=>
CHLA-266 M1n6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;lUWlEPTB;MkeuNUBvVQ>? MYqyN|MxOzd2MR?=
TC-71 M{LwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrtT3pNUUN3ME20MlUhdk1? Ml3DNlM{ODN5NEG=
CHLA-9 NGnR[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX6ZlJKSzVyPUSuOkBvVQ>? MorJNlM{ODN5NEG=
CHLA-10 M4fidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmToTWM2OD13Lkegcm0> MkXqNlM{ODN5NEG=
CHLA-258 NUnvSXZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nQ[GlEPTB;Nj60JI5O MnLNNlM{ODN5NEG=
SJ-GBM2 M2HhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTF{Lkmgcm0> MojUNlM{ODN5NEG=
NB-1643 Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PmbGlEPTB;Nz60JI5O NWjFfW1jOjN|MEO3OFE>
NB-EBc1 NUDjZWF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVroc21JUUN3ME2xOk45KG6P NYC4TmRqOjN|MEO3OFE>
CHLA-90 MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTQTWM2OD1{Mj6zJI5O NW\jUVRCOjN|MEO3OFE>
CHLA-136 NWTGe|ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M320PWlEPTB;MkOuNkBvVQ>? NHjDV3ozOzNyM{e0NS=>
NALM-6 NF7SeWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnQTWM2OD1zMT63JI5O M{jqfVI{OzB|N{Sx
COG-LL-317 NYryfIp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zCSGlEPTB;ND60JI5O M{T4W|I{OzB|N{Sx
RS4;11 NY\CU253T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j5VWlEPTB;MUOuOUBvVQ>? NXu2VpVjOjN|MEO3OFE>
MOLT-4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW3d21KSzVyPUGwMlYhdk1? NXzkcXkyOjN|MEO3OFE>
CCRF-CEM (1) MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe1[IlQUUN3ME2xNk42KG6P MnHUNlM{ODN5NEG=
CCRF-CEM (2) NVnsU3ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTdwMjDuUS=> M3\0UVI{OzB|N{Sx
Kasumi-1 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTVwODDuUS=> M1jReFI{OzB|N{Sx
Karpas-299 NFfER3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7FTWM2OD17Lk[gcm0> Mn;iNlM{ODN5NEG=
Ramos-RA1 NWTSTHc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;BToNEUUN3ME23MlQhdk1? MYmyN|MxOzd2MR?=
LNCaP MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nzcGlEPTB;ODDuUS=> MWqyN|E2OjByNB?=
VCaP MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTdibl2= MYSyN|E2OjByNB?=
H1355 NU\aNYFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDCWFJWUUN3ME21JI5O MXGyN|AyOjJ2OB?=
H157 NVz0cWdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT2W2N7UUN3ME23JI5O Mnv0NlMxOTJ{NEi=
H460 NVLIUm1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf4bmxKSzVyPUigcm0> NWjOOGJMOjNyMUKyOFg>
IA-LM MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;3cYt2UUN3ME2xNEBvVQ>? MkTLNlMxOTJ{NEi=
HOP-62 NYrmelY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHDZm9KUUN3ME2xNUBvVQ>? M3iyT|I{ODF{MkS4
H23 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFzIH7N M4XSbFI{ODF{MkS4
H2030 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\JdWlEPTB;MUKgcm0> NVjm[mh{OjNyMUKyOFg>
H441 M2PaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DJbWlEPTB;MUSgcm0> MUOyN|AyOjJ2OB?=
H2212 NHKxO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv0eppuUUN3ME2xO{BvVQ>? Ml;PNlMxOTJ{NEi=
SK-LU-1 NEGwOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPvdZNKSzVyPUG4JI5O NEPLelMzOzBzMkK0PC=>
H2009 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGW0ZWlKSzVyPUG5JI5O NInDdZQzOzBzMkK0PC=>
H1792 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVniZ5NNUUN3ME2yNEBvVQ>? M3ywc|I{ODF{MkS4
COR-L23 NY\rfolrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PtVmlEPTB;MkKgcm0> NYDWSWppOjNyMUKyOFg>
H727 NXnnemk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ6IH7N M1HQeFI{ODF{MkS4
H1734 Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDKNJdKSzVyPUK4JI5O NFGzWnEzOzBzMkK0PC=>
H358 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7MSHlKSzVyPUK5JI5O NFjMV5ozOzBzMkK0PC=>
A549 M{[5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTR|IH7N MYGyN|AyOjJ2OB?=
H2122 M{PDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTV|IH7N NGjSfnQzOzBzMkK0PC=>
Calu-1 M2HNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke0TWM2OD13ODDuUS=> NFm1WXYzOzBzMkK0PC=>
Calu-6 M37KWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjqN5JKSzVyPU[0JI5O M1e1[FI{ODF{MkS4
NCI-H1975 NFv1PWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUS0PEBp MofUTWM2OD1zNjDuUS=> NHHoUGgzOjF2NE[2OS=>
NCI-H1975 MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzQPYw2PzJiaB?= NGjqSFVKSzVyPUigcm0> M33reFIzOTR2Nk[1

... Click to View More Cell Line Experimental Data

In vivo Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OSA cells
  • Concentrations: 0.001-1μM
  • Incubation Time: 5 days
  • Method: A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female severe combined immune-deficient (SCID) mice
  • Formulation: In DMSO and diluted 1:10 with 20% Cremophor RH 40
  • Dosages: 25 mg/kg/day for 3 days
  • Administration: Tail vein injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 40 mg/mL (109.76 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 364.4
Formula

C20H20N4O3

CAS No. 888216-25-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02637375 Withdrawn Breast Cancer University of Chicago May 2016 Not Applicable
NCT02389751 Active not recruiting Gastroesophageal Junction Adenocarcinoma|Malignant Neoplasm of the Cervical Esophagus|Malignant Neoplasm of the Thoracic Esophagus|Stage IIA Esophageal Cancer AJCC v7|Stage IIB Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7|Stage IIIC Esophageal Cancer AJCC v7 M.D. Anderson Cancer Center|National Cancer Institute (NCI) April 10 2015 Phase 1
NCT02334319 Terminated Stage I Hypopharyngeal Squamous Cell Carcinoma|Stage I Laryngeal Squamous Cell Carcinoma|Stage I Oral Cavity Squamous Cell Carcinoma|Stage I Oropharyngeal Squamous Cell Carcinoma|Stage II Hypopharyngeal Squamous Cell Carcinoma|Stage II Laryngeal Squamous Cell Carcinoma|Stage II Oral Cavity Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma Emory University|Synta Pharmaceuticals Corp. December 2014 Phase 1
NCT02192541 Terminated Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 2 2014 Phase 1
NCT02261805 Terminated Cancer|Small Cell Lung Cancer Georgetown University|Synta Pharmaceuticals Corp. October 2014 Phase 1|Phase 2
NCT02012192 Terminated Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer Medical University Innsbruck|European Commission July 4 2014 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does this inhibitor inhibit both isoforms of HSP90?

  • Answer:

    We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Tags: buy Ganetespib (STA-9090) | Ganetespib (STA-9090) supplier | purchase Ganetespib (STA-9090) | Ganetespib (STA-9090) cost | Ganetespib (STA-9090) manufacturer | order Ganetespib (STA-9090) | Ganetespib (STA-9090) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID